(Total Views: 583)
Posted On: 12/17/2020 6:44:27 AM
Post# of 153977
Dfwl, that was out of context. Sandburg does say,
But he goes on to say:
Quote:
They [investors] believe that the government will act rationally and isn’t responding because the data is poor.
But he goes on to say:
Quote:
What investors are missing about leronlimab is that it has gone through 3 DSMC meetings and got the highest mark which is “continue the study as planned because they are expected to hit their endpoint.” This is a resounding indicator that the drug is making an impact on lowering the mortality rate. This is excellent news given that no other drug is a phase 3 randomized controlled trial has mortality as an endpoint.
(4)
(0)
